HIT! High Impact Clinical Trials – Why and How
9 Feb 2025
9 a.m.
10:30 a.m.
Auditorium Brahmkamal Hall
| Time | Session |
|---|
|
9 a.m.
9:18 a.m.
|
What Have We Learned From CONVINCE?
PeterBlankestijn
Oral Abstract Presenter
P.J.Blankestijn@umcutrecht.nlUniversity Medical Center UtrechtNetherlands
|
|
9:18 a.m.
9:36 a.m.
|
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease
VladoPerkovic
Oral Abstract Presenter
vlado.perkovic@unsw.edu.auUniversity of New South Wales, Sydney, AustraliaAustralia
|
|
9:36 a.m.
9:54 a.m.
|
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
JonathanBarratt
Oral Abstract Presenter
jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
|
|
9:54 a.m.
10:12 a.m.
|
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease
PriscillaSmith
Oral Abstract Presenter
priscilla.smith@kcl.ac.ukKings College Hospital LondonUnited Kingdom
|
|
10:12 a.m.
10:30 a.m.
|
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage
Selvin Sundar RajMani
Oral Abstract Presenter
selvinsr@gmail.comAssociate Professor in Nephrology, Christian Medical College, Vellore, IndiaIndia
|